Cellectar Advances Iopofosine Phase 3 Trial with Mid-2027 FDA Submission Target
Event summary
- Cellectar initiated site activation for a confirmatory Phase 3 trial of iopofosine I 131, targeting a mid-2027 FDA submission under the Accelerated Approval Program.
- Presented CLOVER WaM trial data at ASCO 2026, showing 87.5% overall response rate in relapsed/refractory Waldenström Macroglobulinemia (r/r WM).
- Began Phase 1b trial of CLR 125 in triple-negative breast cancer, dosing first patients.
- Raised $35 million upfront in May 2026 to fund the Phase 3 study, with cash runway into Q2 2027.
The big picture
Cellectar’s progress in iopofosine I 131 reflects the growing emphasis on targeted radiotherapeutics for hematologic cancers. The Phase 3 trial’s success could position the drug as a breakthrough treatment, while the $35 million financing underscores investor confidence in its PDC platform. However, sustaining momentum amid high development costs remains critical.
What we're watching
- Regulatory Milestones
- Whether the Phase 3 trial meets enrollment targets and delivers data supporting a mid-2027 FDA submission.
- Clinical Validation
- How iopofosine I 131’s efficacy in r/r WM translates to other B-cell malignancies, including multiple myeloma.
- Execution Risk
- The pace at which Cellectar advances its radiopharmaceutical pipeline amid rising R&D expenses and cash burn.